drugset / Trial / NCT02362789
Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is designed to explore the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers.
Timeline
- Start
- 2015-01-04
- Primary completion
- 2016-07-15
- Completion
- 2016-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |